FDA Clearance Tracker · P230003-S015
Alinity m HR HPV
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jul 23, 2026
Approved
Time to decision
115 days
Received Mar 30, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230003-S015
- Device name
- Alinity m HR HPV
- Applicant
- Abbott Molecular, Inc.
- Applicant location
- Des Plaines, IL
- Received
- Mar 30, 2026
- Decided
- Jul 23, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P230003
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Requested a site change for the P230003/S015
Source documents
Other decisions for Abbott Molecular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.